XILIO THERAPEUTICS INC (XLO) Stock Price, Quote, News and Overview
NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD
XLO Quote, Performance and Key Statistics
XILIO THERAPEUTICS INC
NASDAQ:XLO (2/12/2025, 10:55:10 AM)
1.29
+0.63 (+95.45%)
The current stock price of XLO is 1.29 USD. In the past month the price decreased by -40.27%. In the past year, price increased by 7.53%.
XLO Latest News and Analysis
Traders are paying attention to the gapping stocks in Wednesday's session.
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Wednesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers.
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with...
XLO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.16 | 342.59B | ||
| AMGN | AMGEN INC | 14.86 | 158.37B | ||
| GILD | GILEAD SCIENCES INC | 22.54 | 129.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1558.55 | 116.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.58 | 73.13B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.33B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.36B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.99B | ||
| NTRA | NATERA INC | N/A | 22.41B | ||
| BIIB | BIOGEN INC | 8.07 | 19.20B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 16.28B |
Related stock screener links
About XLO
Company Profile
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The firm is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Company Info
XILIO THERAPEUTICS INC
828 Winter Street, Suite 300
Waltham MASSACHUSETTS US
Employees: 73
Company Website: https://xiliotx.com/
Investor Relations: https://ir.xiliotx.com/
Phone: 16174304680
XLO FAQ
What is the stock price of XLO?
The current stock price of XLO is 1.29 USD.
What is the symbol for XILIO THERAPEUTICS INC stock?
The exchange symbol of XILIO THERAPEUTICS INC is XLO and it is listed on the Nasdaq exchange.
On which exchange is XLO stock listed?
XLO stock is listed on the Nasdaq exchange.
Is XLO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for XLO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of XLO.
Does XLO stock pay dividends?
XLO does not pay a dividend.
What is the Price/Earnings (PE) ratio of XLO?
XLO does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
What is the Short Interest ratio of XLO stock?
The outstanding short interest for XLO is 0.81% of its float.
XLO Technical Analysis
XLO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XLO. While XLO seems to be doing ok healthwise, there are quite some concerns on its profitability.
XLO Financial Highlights
Over the last trailing twelve months XLO reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by 41.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.12% | ||
| ROE | -299.43% | ||
| Debt/Equity | 0 |
XLO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to XLO. The Buy consensus is the average rating of analysts ratings from 7 analysts.